Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bill Gates Backs mRNA Capacity In India, Pitches Cutting Gene Therapy Cost

Executive Summary

Billionaire philanthropist and co-chair of the Bill and Melinda Gates Foundation signals efforts underway to support building mRNA capacity in India amid the new platform’s potential beyond COVID-19 vaccines. He also highlights the need to bring down sharply the cost of gene therapies.

You may also be interested in...



Co-Inventor Of mRNA Tech Goes After Sickle Cell Anemia

After a chance encounter at a photocopy machine brewed the recipe for Pfizer and Moderna’s success with mRNA vaccines, Dr Drew Weissman has set sights on developing a single-injection therapy for sickle cell anemia.

Afrigen Chief On mRNA Vaccine Candidate, IP Hoops, Market-Shaping Efforts

Petro Terblanche, managing director of Afrigen Biologics, talks to Scrip about a range of critical issues pertaining to the mRNA COVID-19 vaccine candidate being progressed under the wider WHO-backed technology hub initiative in South Africa and which is based on publicly-available Moderna data. Various tools and approaches are on hand to tackle the labyrinth of patents involved, though the hub, the executive underscores, will not infringe intellectual property rights.

Yes We Can: South African Scientists On Their Way With mRNA Vaccine

South African researchers make own version of mRNA COVID-19 vaccine that uses “recipes” available in the public domain but one that is eventually expected to be “second generation” and can be more applicable to use in low- and middle-income countries. The initiative, under the wider WHO-backed mRNA vaccine technology hub, doesn’t see Moderna or BioNTech intellectual property as being a barrier.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel